drugset / Trial / NCT03972462

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

NCT03972462

Phase 1 Completed 12 enrolled Nobelpharma
Non-randomizedSequentialOpen-labelOther

Summary

This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.

Timeline

Start
2019-05-31
Primary completion
2019-06-17
Completion
2019-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 1.6 mg Topical
Subject Sirolimus Small molecule 2 mg Topical

Indications

No indication recorded.